Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures

Current Rheumatology Reports

Volumn 9, Issue 1, 2007, Pages 50-56

  Schousboe, John T ^a  

^a PARK NICOLLET INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FRAGILITY FRACTURE; HEALTH CARE SYSTEM; HIP FRACTURE; HUMAN; MONOTHERAPY; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; BONE DENSITY; COST-BENEFIT ANALYSIS; DRUG THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MALE; MARKOV CHAINS; MODELS, BIOLOGICAL; MODELS, ECONOMIC; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 34249279890     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0022-1     Document Type: Article

References (8)

1. •• Stevenson M, Lloyd Jones M, De Nigris E, et al.: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005, 9:1-160. This is the most comprehensive, recent treatise on the cost-effectiveness of therapy to prevent osteoporotic fracture, including extensive meta-analyses of the fracture reduction benefit from currently available pharmacologic agents.
2. • Schousboe JT, Ensrud KE, Nyman JA, et al.: Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005, 53:1697-1704. This study is the only cost-effectiveness modeling study to date with a lifetime horizon to examine the cost-effectiveness of universal bone densitometry followed by treatment of those with osteoporosis among community dwelling and nursing home resident subsets of elderly women.
3. • Liu H, Michaud K, Nayak S, et al.: The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006, 166:1209-1217. This is the most comprehensive evaluation of the cost-effectiveness published to date of teriparatide to prevent osteoporotic fracture. The model used in the study includes a sequential strategy of teriparatide followed by alendronate therapy and compares use of teriparatide to alendronate alone rather than just to no therapy.
4. • Schousboe JT, Ensrud KE, Nyman JA, et al.: Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study. J Clin Densitom 2006, 9:133-143. The only published study thus far to examine the cost effectiveness of spinal imaging at the point of service of bone densitometry to detect those with a prevalent vertebral fracture among those who do not have osteoporosis by BMD criteria.
5. Borgstrom F, Johnell O, Kanis JA, et al.: Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmaco-economics 2004, 22:1153-1165.
6. •• Kanis JA, Johnell O, Oden A, et al.: Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 2005, 16:6-14. An important modeling study of how to cost-effectively select cohorts of both men and women for drug therapy based on their 10-year absolute risk of hip fracture.
7. • Borgstrom F, Johnell O, Kanis JA, et al.: At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006, 17:1459-1471. Another important study showing the variability of absolute hip fracture risk thresholds from country to country at which drug therapy to prevent osteoporotic fracture may be cost-effective, and important determinants of that variability.
8. • Borgstrom F, Zethraeus N, Johnell O, et al.: Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006, 17:637-650. The most comprehensive study to date yielding empiric estimates of the costs and disutility of fractures within the Swedish population, including indirect costs and costs of informal care.